All In Biotech

Drug Trial Radar · NCT07778836

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 5, 2026

Primary completion

Jul 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Larimar Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of subcutaneous nomlabofusp in adult and pediatric subjects with Friedreich's ataxia

Conditions

  • Friedreich Ataxia
  • Friedreich's Ataxia

Interventions

  • NomlabofuspDrug

    Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.

  • PlaceboDrug

    The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Upright Stability Score (USS) subscale E of modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)Time frame: Baseline, Weeks 12, 24, 36, 48, 72
  2. Change from baseline in the total modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)Time frame: Baseline, Weeks 12, 24, 36, 48, 72

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Morsani Center for Advanced Health Care, University of South Florida Health

    Tampa, Florida · Recruiting

  • Northwestern Medical Group, Department of Neurology

    Chicago, Illinois · Recruiting

  • Clinilabs

    Eatontown, New Jersey · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.